Coverage
-
December 22, 2015
A Tennessee federal judge gave his final approval Tuesday for a $9 million agreement reached between Mutual Pharmaceutical Co. Inc. and an end-payor class to settle claims the company colluded with Pfizer Inc. unit King Pharmaceuticals Inc. to delay generic versions of the muscle relaxant Skelaxin, saying it was fair.
13 other articles on this case.
View all »